GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Stevanato Group SPA (NYSE:STVN) » Definitions » Float Percentage Of Total Shares Outstanding

Stevanato Group SPA (Stevanato Group SPA) Float Percentage Of Total Shares Outstanding : 17.77% (As of May. 24, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Stevanato Group SPA Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Stevanato Group SPA's float shares is 48.46 Mil. Stevanato Group SPA's total shares outstanding is 272.77 Mil. Stevanato Group SPA's float percentage of total shares outstanding is 17.77%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Stevanato Group SPA's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Stevanato Group SPA's Institutional Ownership is 13.50%.


Stevanato Group SPA Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Stevanato Group SPA's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=48.46/272.77
=17.77%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Stevanato Group SPA (Stevanato Group SPA) Business Description

Industry
Traded in Other Exchanges
Address
Via Molinella 17, Piombino Dese, Padua, ITA, 35017
Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. Stevanato's revenue is geographically diversified, with 60% of sales from Europe, the Middle East and Africa (EMEA), 27% in North America, 10% in Asia-Pacific (APAC), and 3% from South America. It has two segments Biopharmaceutical and Diagnostic Solutions and Engineering.